Page 292«..1020..291292293294..300310..»

BTIG to Host Biotechnology Conference on August 8-9, 2022 – Business Wire

Posted: August 14, 2022 at 1:50 am

NEW YORK--(BUSINESS WIRE)--BTIG announced today that it will hold its annual Biotechnology Conference on Monday, August 8th and Tuesday, August 9, 2022, in New York. The firm will host over 125 established and emerging healthcare company management teams for one-on-one investor meetings and thematic panel discussions with industry leaders. Panel themes will include biotech policy updates, KRAS targeting modalities, immuno-oncology, pulmonary medication development, cell therapy advancements, CNS AAV gene therapy developments, retinal disease developments, buyside biotech investor sentiment and more.

The conference will be hosted by:

Our biotechnology team has attracted some of the industrys most respected thought leaders and corporate management teams to participate in our upcoming conference, commented Ryan Serwin, CFA, Director of Research at BTIG. We look forward to producing this hybrid event, where we bring together key public and private biotechnology companies with institutional investors to explore emerging innovations and discuss impactful trends across the industry.

For more information about the conference, email info@btig.com. Please note that participants must be pre-registered to attend. To access BTIG insights, contact a firm representative or log in to http://www.btigresearch.com.

About BTIG

BTIG is a global financial services firm specializing in institutional trading, investment banking, research, and related brokerage services. With an extensive global footprint and more than 750 employees, BTIG, LLC and its affiliates operate out of 23 cities throughout the U.S., and in Europe, Asia, and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency, and commodities (futures, commodities, foreign exchange, interest rates, credit, and convertible and preferred securities). The firms core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more.

Disclaimer: https://www.btig.com/disclaimer. To learn more about BTIG, visit http://www.btig.com.

Read more here:
BTIG to Host Biotechnology Conference on August 8-9, 2022 - Business Wire

Posted in Biotechnology | Comments Off on BTIG to Host Biotechnology Conference on August 8-9, 2022 – Business Wire

University of Rwanda to introduce master’s programme in biotechnology – The New Times

Posted: August 14, 2022 at 1:50 am

Officials at the University of Rwanda (UR) have said they are ready to roll out a masters degree in biotechnology, the field of study that could boost treatment of deadly diseases in the future.

This was highlighted in Kigali on Friday, August 12 at the end of weeklong deliberations about the implementation of the biotech programme, in which dozens of academics from Rwanda and foreign universities, policy makers, scientists and development partners took part.

The first cohort of candidates for the master's degree could begin their studies inearly 2023,The New Timeshas learnt.

Rwanda needs experts in biotechnology more than ever as the country embarks on developing its capacity invaccine manufacturingand genetic engineering, the officials said.

Locally trained scientists and biotech engineers could drive research in medical treatments, agriculture, foodprocessing and waste management, among other sectors.

The UR already has a bachelors programme in biotechnology. But it only offers basic skills, which are limited in terms of research and manufacturing, the officials said.

When it comes to manufacturing of vaccines or developing a nationwide industry in food processing, these are no longer fields which can be run by someone with a bachelor's degree, because they have just the foundational skills," Dr. Ignace Gatare, the Principal of UR's College of Science and Technology, toldThe New Times.

"So, with the current move to produce vaccines locally, and you have heard about the manufacturing of seeds which are resistant to climate change, it is necessary to train another highly skilled pool of professionals and that happens only at masters and PhD levels.

He added that the PhD programme would start once masters is deemed successful.

At least 834,000 (about Rwf880 million), as part of the European Unions7 million funding for capacity buildingin vaccines production in Rwanda, has been earmarked for the program to start operations.

The programme, which awaits the university senate approval, will enrol a cohort of 20-30 students, Gatare said, and could even start later this year, if everything goes according to plan.

Incorporated in three UR colleges, the programme will be hosted at the College of Science and Technology in Kigali.

According to the officials, parastatals, such as the Rwanda Biomedical Centre, Rwanda Food and Drugs Authority and Rwanda Agriculture and Animal Resources Board, will be some of the beneficiaries of the biotech programme.

Players in the Rwandan health sector have welcomed the initiative saying it would not only improve treatment of diseases but also boost research in emerging diseases.

In the 1990s, most of the diseases we treated were malaria, typhoid, meningitis and others, which are no longer prevalent, said Dr. Jean Nyirinkwaya, a long-time investor in the local health industry.

But today, there are other emerging diseases, affecting the heart, kidneys and which require better treatment or transplantation. Theres also need to carry out more research to understand why some of these diseases affect people in different categories. The masters programme in biotechnology comes at the right time.

[emailprotected]

See the original post here:
University of Rwanda to introduce master's programme in biotechnology - The New Times

Posted in Biotechnology | Comments Off on University of Rwanda to introduce master’s programme in biotechnology – The New Times

Long COVID-19 and other chronic respiratory conditions after viral infections may stem from an overactive immune response in the lungs – The…

Posted: August 5, 2022 at 2:55 am

Viruses that cause respiratory diseases like the flu and COVID-19 can lead to mild to severe symptoms within the first few weeks of infection. These symptoms typically resolve within a few more weeks, sometimes with the help of treatment if severe. However, some people go on to experience persistent symptoms that last several months to years. Why and how respiratory diseases can develop into chronic conditions like long COVID-19 are still unclear.

I am a doctoral student working in the Sun Lab at the University of Virginia. We study how the immune system sometimes goes awry after fighting off viral infections. We also develop ways to target the immune system to prevent further complications without weakening its ability to protect against future infections. Our recently published review of the research in this area found that it is becoming clearer that it might not be an active viral infection causing long COVID-19 and similar conditions, but an overactive immune system.

Keeping your immune system dormant when there isnt an active infection is essential for your lungs to be able to function optimally.

Your respiratory tract is in constant contact with your external environment, sampling around 5 to 8 liters (1.3 to 2 gallons) of air and the toxins and microorganisms in it every minute. Despite continuous exposure to potential pathogens and harmful substances, your body has evolved to keep the immune system dormant in the lungs. In fact, allergies and conditions such as asthma are byproducts of an overactive immune system. These excessive immune responses can cause your airways to constrict and make it difficult to breathe. Some severe cases may require treatment to suppress the immune system.

During an active infection, however, the immune system is absolutely essential. When viruses infect your respiratory tract, immune cells are recruited to your lungs to fight off the infection. Although these cells are crucial to eliminate the virus from your body, their activity often results in collateral damage to your lung tissue. After the virus is removed, your body dampens your immune system to give your lungs a chance to recover.

Over the past decade, researchers have identified a variety of specialized stem cells in the lungs that can help regenerate damaged tissue. These stem cells can turn into almost all the different types of cells in the lungs depending on the signals they receive from their surrounding environment. Recent studies have highlighted the prominent role the immune system plays in providing signals that facilitate lung recovery. But these signals can produce more than one effect. They can not only activate stem cells, but also perpetuate damaging inflammatory processes in the lung. Therefore, your body tightly regulates when, where and how strongly these signals are made in order to prevent further damage.

While the reasons are still unclear, some people are unable to turn off their immune system after infection and continue to produce tissue-damaging molecules long after the virus has been flushed out. This not only further damages the lungs, but also interferes with regeneration via the lungs resident stem cells. This phenomenon can result in chronic disease, as seen in several respiratory viral infections including COVID-19, Middle East Respiratory Syndrome (MERS), respiratory syncytial virus (RSV) and the common cold.

In our review, my colleagues and I found that many different types of immune cells are involved in the development of chronic disease after respiratory viral infections, including long COVID-19.

Scientists so far have identified one particular type of immune cells, killer T cells, as potential contributors to chronic disease. Also known as cytotoxic or CD8+ T cells, they specialize in killing infected cells either by interacting directly with them or by producing damaging molecules called cytokines.

Killer T cells are essential to curbing the virus from spreading in the body during an active infection. But their persistence in the lungs after the infection has resolved is linked to extended reduced respiratory function. Moreover, animal studies have shown that removing killer T cells from the lungs after infection may improve lung function and tissue repair.

Another type of immune cells called monocytes are also involved in fighting respiratory infections, serving among the first responders by producing virus- and tissue-damaging cytokines. Research has found that these cells also continue to accumulate in the lungs of long COVID-19 patients and promote a pro-inflammatory environment that can cause further damage.

Understanding the immunological mechanisms underlying long COVID-19 is the first step to addressing a quickly worsening public health problem. Identifying the subtle differences in how the same immune cells that protect you during an active infection can later become harmful could lead to earlier diagnosis of long COVID-19. Moreover, based on our findings, my team and I believe treatments that target the immune system could be an effective approach to manage long COVID-19 symptoms. We believe that this strategy may turn out to be useful not only for COVID-19, but also for other respiratory viral infections that lead to chronic disease as well.

The rest is here:
Long COVID-19 and other chronic respiratory conditions after viral infections may stem from an overactive immune response in the lungs - The...

Posted in Stem Cells | Comments Off on Long COVID-19 and other chronic respiratory conditions after viral infections may stem from an overactive immune response in the lungs – The…

Buffalo center fuels research that can save your life from heart disease and stroke – Buffalo News

Posted: August 5, 2022 at 2:52 am

Dr. Jennifer Lang splits most of her work life treating patients at Gates Vascular Institute and conducting research in her lab several floors up in the same building.

UB medical physics students Simon Wu and Emily Vanderbelt work with flow-through 3D-printed aneurysm models using X-rays in the Canon Stroke & Vascular Research Center, part of the University at BuffaloClinical and Translational Research Center on the Buffalo Niagara Medical Campus.

The arrangement suits her well as she continues promising research to learn if a stem cell-derived treatment can repair damaged heart tissue.

Lang, a cardiologist, and her University at Buffalo team, face a dilemma: The immune system revs into high gear when the heart suffers a serious setback, limiting the power of stem cells to heal.

The daunting task seems more surmountable these days because she works in a building filled with researchers of all stripes.

I do collaborations with groups that I otherwise wouldn't have. Its led to some really new, interesting results, said Lang, assistant professor in the UB Jacobs School of Medicine and Biomedical Sciences who practices with UBMD Internal Medicine and at the Buffalo VA Medical Center.

People are also reading

This day, a surgical team worked seamlessly to monitor her vital signs and feather a medical device through a catheter into the left side of her damaged heart. The procedure slowed her heartrate so her organs could take a couple of days to re-collect themselves and give her a fighting chance to recover.

UB-fueled research unfolds on floors five through eight of the building at 875 Ellicott St., alongside Buffalo General Medical Center.

Ten years ago, the university invested $118 million into its Clinical and Translational Research Center, and about $25 million for equipment came from industry partners who wanted to join forces with physicians, engineers and others in the science fields.

The center became the first major pieceof the UB medical school to move onto the downtown Buffalo Niagara Medical Campus, followed in late 2017 by the $375 million Jacobs School teaching and research complex, around the corner at Main and High streets.

Both foster translational medicine, which combines disciplines, resources and techniques to move benchtop research to the patient bedside, eventually strengthening community health.

Langs work symbolizes the approach.

The Buffalo native can see her high school alma mater, City Honors, from her workplace. She went to Cornell University as an undergraduate and returned to Buffalo to go to medical school. Buoyed by fellow UB students, faculty and mentors, she chose to stay in the city for her internal medicine residency and cardiology fellowship.

Lang did her classroom work and research on the UB South Campus and most of her clinical work 8 miles away, on the downtown Medical Campus.

Stairs and elevators are the only things that separate her from most of her collaborators and patients today.

I moved into this building when it opened 10 years ago, she said. At the time, I was completing my cardiology fellowship. There was a physical divide, so I was thrilled with the new arrangement. Things can happen in parallel now.

Dr. Timothy Murphy, left, director of theUB Clinical and Translational Research Center in Buffalo, works with research technician Charmaine Kirkham in their lab, which focuses on potential treatments forchronic obstructive pulmonary disease (COPD).

That was the plan, said Dr. Timothy Murphy, director of the UB Clinical and Translational Research Center.

Clinical research and health care have become more and more seamlessly integrated, he said. The building contributed to that.

Murphy, another regional native, was among those who shared and helped carry out the vision of Gates Vascular Institute founder Dr. L. Nelson Nick Hopkins III, who chaired the UB Department of Neurosurgery from 1989 to 2013 and wanted to create a more innovative vascular center.

Murphy moved his lab in 2006 from the VA Medical Center near South Campus to the UB Center for Bioinformatics and Life Sciences on the Medical Campus, so he could be involved in the design of the UB research center, on floors above Gates Vascular, as well as at the Jacobs School particularly its labs.

They always talked about physicians and researchers bumping into each other, talking to each other, and having graduate students and postdocs and technicians talk to each other, Murphy said. Having done it now for all these years, I see it really does work.

He and his research team continue a 20-year study on the bacterial infection that causes COPD in hopes it will help lead to vaccines that prevent the infection and new treatments to clear the bacteria from the lower airway.

As senior associate dean forclinical and translational researchat the Jacobs School, he is also the point person for coordinating UB-related clinical trials and encouraging collisions between health care researchers on the Medical Campus and around the world.

There were 70 such trials on the Medical Campus in 2015, when the building where he works was in its infancy. Today, there are more than 200.

"Things can happen in parallel now," says Dr. Jennifer Lang, a cardiologist, researcher and University at Buffalo assistant professor who splits her research and clinical time in the same building on the Buffalo Niagara Medical Campus.

Labs focused on obstetric and gynecological advances and keys to healthy aging occupy space near his seventh-floor lab.

The Clinical and Translational Research Center was established in 2012. UB added a biobank in 2019 to store medical specimens for ongoing clinical studies.

Its collaborative framework helped UB land a $15 million Clinical and Translational Science Awardin 2015 from the National Institutes of Health (NIH) to encourage research efforts across university departments and specialties to boost innovation, speed development of medical treatments, and reduce health disparities in poor, rural and minority communities.

The five-year grant was renewed in 2020 with nearly $22 million more, encouraging Buffalo-based researchers to work with others who got awards, including researchers with Harvard, Johns Hopkins, Stanford and Yale universities.

A printer creates a 3D model, slice by slice, at the Canon Stroke & Vascular Research Center in the University at Buffalo Clinical and Translational Research Center. Lab researchers experiment with different mixtures of six polymers to make the most malleable and useful models for medical research.

Throughout the building, the goal is to improve medical devices and treatments that make an impact in the clinics and catheter suites in the Gates Vascular Institute on the floors below the research center and provide data and education that informs others, including patients.

The eighth-floor Canon Stroke & Vascular Research Center, which tops the UB research center, is a case in point.

Ciprian Chip Ionita, its director, came to UB from Romania in 1999 and worked his first dozen years on the South Campus.

We were the first ones to move in, said Ionita, assistant professor of biomedical engineering and member of the medical school's Department of Neurosurgery.

The lab was designed to help innovate and improve medical devices and neurovascular procedures.

Part of its work involves using MRIs, CT scans and other radiological images of Gates Vascular patients to create 3D-printed models of the circulatory system and heart.

3D printing created this replica of part of a patient's spinal column at the Canon Stroke & Vascular Research Center. Researchers there push the boundaries until their findings are refined to the point where they can be applied to model-making on two highly calibrated 3D printers in the Jacobs Institute downstairs from the lab that meet FDA standards. We fail up here about 90% of the time, says Ciprian Chip Ionita, lab director. They fail maybe 1%, so were testing everything that's possible.

Medical school and other lab researchers use the models produced here to better understand how anatomy and disease of former and current patients led to poor health and, in some cases, poor surgical outcomes.

Gates Vascular surgeons also can use 3D models that replicate the anatomy of patients awaiting surgery to practice feathering catheters and medical devices through bends, nooks and crannies of the blood vessels, and deploy medical devices in spines and the circulatory system as they maneuver past muscles, bones, blockages and other obstructions that might come into play.

During practice interventions, we analyze everything, Ionita said, because we can go into these models with sensors to measure blood flow, blood pressure and more.

You can create a model that says, Here's somebody who has a carotid artery that's 50% (blocked) and he's 50 years old, Ionita said. Or we can say, 'Here is a young person in their 20s, and is fully compliant, no stenosis or whatever.' And those mechanical properties are translated by the printer.

Even cadaver donors cant do that.

The goal is to lower the rate of complications and be successful in one shot during a procedure, said Ionita, who supervises up to 10 graduate biomedical engineering students, and roughly 20 undergraduate, graduate and medical school students.

Those who pay close attention to 3D models and other medical research based on data from patients treated in the building include Dr. Elad Levy, co-director of the Gates Vascular Stroke Center; Dr. Adnan Siddiqui, director of neurological and stroke services at Kaleida Health; and Dr. Vijay Iyer, medical director of cardiology and the Structural Heart Program at Kaleida. All three have ties to UB.

Even here, Ionita said, physician-scientists and other researchers see the damage that smoking, high blood pressure and living in ZIP codes where poverty is rampant can create complications that lead to worse health and surgical outcomes.

Eric Wozniak, a senior research and development technician in the Idea to Reality lab at the Jacobs Institute, uses a microscope as he works to improve catheter technology.

Doctors and staff improve treatment protocols and surgical prowess with help from those who work on the top half of the building for UB and the Jacobs Institute. The latter is named for Dr. Lawrence D. Jacobs, a Buffalo neurosurgeon whose research led to the first treatments for multiple sclerosis.

Four years after Jacobs died in 2001, his brother Jeremy, chair of the Delaware North Cos. and the UB Council, approached the university about creating a lasting memorial for the respected physician. He later signed on to the concept of creating a multidisciplinary vascular center, starting with a $10 million donation for the institute that bears the family name.

The institute includes an atrium, caf and glass-walled spaces that overlook procedure rooms on the floor below. It has 50 employees, including more than 30 biomedical and electrical engineers, who seek company-sponsored research funding, help collect data and make prototypes for clinical trials, and work with researchers to publish their work in medical journals.

In 2016, the institute was designated a 3D Printing Center of Excellence in Health Care by Israeli-based Stratasys Ltd., a leading 3D printing-maker. In early 2018, it created a proof-of-concept Idea to Reality Center, known as i2R, to further improve medical devices and surgical techniques in the vascular space.

This is our secret sauce lab, said Siddiqui, Jacobs Institute CEO. There's nothing we do downstairs that we could not do better.

This is a device designed and built in the Idea 2 Reality lab at the Jacobs Institute in Buffalo. The lab improves medical devices and technology used in vascular procedures and treatments.

Dr. Carlos Pena, who ran the FDA Neurologic Devices Division for 15 years, joined the institute staff last year to improve the chances technology conceived and designed with help from the institute gets to market.

Every company wants to talk to him, Siddiqui said. He tells them what testing needs to be done. Some of that gets done in-house. A lot of it goes to the university or, when they have a clinical trial, that gets done downstairs so the entire ecosystem is functioning, I think better than Nick Hopkins ever imagined.

Lang, the cardiologist, doesnt miss her former workday commutes. She loves the design and location of the building that sets the standard for vascular care.

Most of her days mix benchtop research in her lab and patient visits and procedures on the floors below. When there is time, she can visit her husband, Fraser Sim, neuroscience director and associate professor at the medical school.

Because we're in such close proximity to the Jacobs School now, we're also really able to engage the medical students earlier in their careers and encourage more research, Lang said. And because we're so close to the hospital, we're able to involve medical residents and fellows in our research projects much more than ever before.

University at Buffalo medical school postdoctoral research associateToubaTarvirdizadeh focuses on cardiac research in the lab of Dr. Jennifer Lang at the UB Clinical and Translational Research Center in Buffalo.

She has spent a decade trying to find better ways for a stem cell derivative that can withstand an immune response and rejuvenate heart tissue without major complications, a result that could help patients recover from a heart attack and lessen the strain of heart failure.

Four years ago, Lang and her doctoral student researcher, Kyle Mentkowski, discovered a way that lowered the immune response in mice that received the derivative.

Mentkowski, now a post-doctorate researcher at Harvard-affiliated Massachusetts General Hospital, was talking with another group of student researchers in the building when they thought it might be a good idea to bring Dr. Jessica Reynolds, an immunologist and UB medical school associate professor, into the research.

The collaboration created robust, reproducible results in mice models, Lang said, and the start of testing in human immune cells she and her colleagues hope can benefit patients within the next decade.

Collaborators now regularly get together to chat at the Jacobs Institute.

The NIH seems very interested in this as a potential clinical therapy, Lang said, but the field as a whole is still in the beginning stages of understanding where we need to go next.

Dr. Aaron Hoffman, left, University at Buffalo medical school associate professor of surgery, and Dr. Kenneth Snyder, UB associate professor of neurosurgery, chat during a break in the Jacobs Institute atrium.

UB researchers have shared some of their findings with researchers making similar inroads elsewhere, she said, and the work spawned other collaborations with Reynolds, her research team and scientists in the UB Department of Biomedical Engineering.

This type of unplanned interaction is not a unique occurrence in this building, Lang said. Our story is just one of many.

The smart way to start your day. We sift through all the news to give you a concise, informative look at the top headlines and must-read stories every weekday.

Read the original:
Buffalo center fuels research that can save your life from heart disease and stroke - Buffalo News

Posted in Delaware Stem Cells | Comments Off on Buffalo center fuels research that can save your life from heart disease and stroke – Buffalo News

California man appears to be another person cured of HIV after a stem cell transplant – aidsmap

Posted: August 5, 2022 at 2:51 am

A man in southern California, dubbed the 'City of Hope patient', appears to be the latest person cured of HIV after receiving a stem cell transplant from a donor with a rare mutation, bringing the total to five, according to a presentation on Monday at the24th International AIDS Conference (AIDS 2022)in Montreal. The man remains free of HIV more than 17 months after stopping antiretroviral therapy (ART) and his leukaemia also remains in remission.

The man is older than the handful of other people previously cured after such a procedure, he has been living with HIV longer and he received a less harsh conditioning regimen prior to the transplant. This suggests that this approach may be possible for a wider subset of HIV-positive people with advanced cancer, but it is far from feasible for the vast majority of people living with HIV. Yet the case could provide clues that help researchers develop more widely applicable approaches for long-term HIV remission.

Dr Jana Dickter talks about the 'City of Hope patient' at AIDS 2022.

The City of Hope patients case, if the right donor can be identified, may open up the opportunity for more older patients living with HIV and blood cancers to receive a stem cell transplant and go into remission for both diseases, said DrJana Dickter of the City of Hope cancer centrenear Los Angeles, who described the case at the conference and at an advance media briefing last week.

The latest case involves a 66-year-old white man who was diagnosed with HIV in 1988. At one point, his CD4 count fell so low (below 100) that he was diagnosed with AIDS. He started ART when it became available in the mid-1990s. In 2018, he was diagnosed with acute myelogenous leukaemia.

Cells from which all blood cells derive. Bone marrow is rich in stem cells.

A protein on the surface of certain immune system cells, including CD4 cells. CCR5 can act as a co-receptor (a second receptor binding site) for HIV when the virus enters a host cell. A CCR5 inhibitor is an antiretroviral medication that blocks the CCR5 co-receptor and prevents HIV from entering the cell.

The disappearance of signs and symptoms of a disease, usually in response to treatment. The term is often used in relation to cancer, indicating that there is no evidence of disease, although the possibility of cancer remaining in the body cannot be ruled out. In HIV, remission is an alternative term for functional cure. A sustained ART-free remission would boost the immune system to induce long-term control of HIV, allowing a person living with HIV to maintain an undetectable viral load without daily medication.

In cell biology, a structure on the surface of a cell (or inside a cell) that selectively receives and binds to a specific substance. There are many receptors. CD4 T cells are called that way because they have a protein called CD4 on their surface. Before entering (infecting) a CD4 T cell (that will become a host cell), HIV binds to the CD4 receptor and its coreceptor.

The use of drugs to treat an illness, especially cancer.

In early 2019, at age 63, he received a stem cell transplant from an unrelated donor with a double CCR5-delta-32 mutation, which deletes the receptors most strains of HIV use to enter cells. Before the procedure, he underwent reduced-intensity conditioning chemotherapy designed for older and less fit patients, and he developed only mild graft-versus-host disease, a condition that occurs when donor immune cells attack the recipients body.

Tests showed that the man achieved 100% chimerism, meaning all his immune cells originated from the donor, Dickter reported. He continued ART (dolutegravir, tenofovir alafenamide and emtricitabine) for two years after the transplant. At that point, with a stable undetectable viral load, he and his doctors decided to try a carefully monitored treatment interruption.

More than three years after the transplant and over 17 months after stopping antiretrovirals he has no evidence of HIV RNA viral load rebound and no detectable HIV DNA in peripheral blood cells, a marker of the latent viral reservoir. Gut tissue biopsies also found no evidence of replication-competent virus.

Laboratory studies showed that his new blood cells were impervious to HIV strains that use the CCR5 receptor. However, Dickter noted that the man might remain susceptible to infection with virus that uses the alternative CXCR4 receptor, so she has counselled him about using PrEP (regular medication to prevent HIV infection).

Whats more, the man shows no detectable HIV-specific T-cell responses and his HIV antibody level has declined over time. Interestingly, he does continue to have antibodies against hepatitis B virus, even though the donor is HBV-negative.

We were thrilled to let him know that his HIV is in remission and he no longer needs to take antiretroviral therapy that he had been on for over 30 years, Dickter said in a City of Hope press release. He saw many of his friends die from AIDS in the early days of the disease and faced so much stigma when he was diagnosed with HIV in 1988. But now, he can celebrate this medical milestone.

The man, who wishes to remain anonymous, added, When I was diagnosed with HIV in 1988, like many others, I thought it was a death sentence, I never thought I would live to see the day that I no longer have HIV.

Only a small number of people have been cured of HIV after stem cell transplants. The first, Timothy Ray Brown, formerly known as the Berlin patient, received two transplants to treat leukaemia in 2006. His oncologist, DrGero Htter, came up with the idea of using stem cells with the CCR5-delta32 mutation, speculating that it might cure both cancer and HIV.

As described at the 2008 Conference on Retroviruses and Opportunistic Infections (CROI), Brown first underwent intensive chemotherapy and whole-body radiation, and he developed near-fatal graft-versus-host disease. He stopped ART at the time of his first transplant, at age 40, but his viral load did not rebound. Researchers extensively tested his blood, gut and other tissues, finding no traces of replication-competent HIV. At the time of his death in September 2020, due to a recurrence of leukaemia, Brown had been free of HIV for more than 13 years.

A second man, Adam Castillejo, dubbed the London Patient, was also cured after receiving a stem cell transplant to treat Hodgkin lymphoma. As described at CROI 2019, he too received cells from a donor with the CCR5-delta-32 mutation, but he had less aggressive conditioning chemotherapy and developed milder graft-versus-host disease. A year and a half after the transplant, with no evidence of viable HIV, he stopped ART in September 2017, and he has now been HIV-free for more than four years.

At this years CROI, New York City researchers described a middle-aged woman with leukaemia who received a transplant using a combination of umbilical cord blood cells with the CCR5-delta-32 mutation and partially matched adult stem cells from a relative. She received intensive chemotherapy and radiation prior to the transplant but did not develop graft-versus-host disease, which is less common with cord blood. She stopped ART three years after the transplant and her viral load remains undetectable a year and a half later.

Finally, a German man, dubbed the Dsseldorf Patient, has not experienced HIV rebound more than three years after stopping ART following a CCR5-delta-32 stem cell transplant. Less is known about this case, which has not receive widespread media attention, but DrBjrn Jensen told NBC News that the man is almost definitely cured.

These cures are no longer anecdotal we now have a real case series, DrSteven Deeks of the University of California at San Francisco told aidsmap. That this approach is curative is no longer really questioned.

Researchers are still working to learn why these cures after stem cell transplantation were successful while other attempts have failed. Using stem cells with a double CCR5-delta-32 mutation seems to be key. At CROI 2012, researchers described two HIV-positive men in Boston who received stem cell transplants for cancer treatment from donors without the mutation. Both experienced viral rebound after stopping ART, though this was delayed.

Some have posited that the graft-versus-host reaction might play a role in eradicating HIV, but the five patients who were cured received different pre-transplant conditioning regimens and some experienced mild or no graft-versus-host disease.

Even as each new case provides more answers, stem cell transplants remain far too risky for people who do not need them to treat life-threatening cancer. Seeing the host as foreign, the donor immune cells can attack the recipients tissues and organs, which may necessitate immunosuppressive therapy. While waiting for donor cells to engraft, patients are highly susceptible to infections. Whats more, the procedure is medically intensive and costly and would be impossible to scale up to treat the millions of people living with HIV worldwide.

Nonetheless, each case offers clues that could help researchers develop strategies that lead to more widely applicable functional cures, or long-term remission without ART. Deeks, for example, hopes emerging gene-editing technologies might be used to delete or disable CCR5 receptors and make an individuals own immune cells resistant to HIV entry.

These cases are still interesting, still inspiring and illuminate the search for a cure, International AIDS Society president-elect DrSharon Lewin of the Peter Doherty Institute for Infection and Immunity in Melbourne told reporters during an AIDS 2022 advance media briefing.

But some advocates question why these rare cures, which wont help most people living with HIV, get so much more attention than natural or post-treatment controllers, one of whom was also described at the conference.

I think theyre selling us a bill of goods, DARE-CAB member Michael Louella said during the discussion following the presentation. Im never going to get that [a stem cell transplant], but this other type of remission that doesnt get so much attention could be applicable for more people.

Read the original here:
California man appears to be another person cured of HIV after a stem cell transplant - aidsmap

Posted in Stem Cell Therapy | Comments Off on California man appears to be another person cured of HIV after a stem cell transplant – aidsmap

Induced Pluripotent Stem Cell (iPSC) Global Market to Reach $3.57 Billion by 2026 – Benzinga

Posted: August 5, 2022 at 2:51 am

Dublin, Aug. 01, 2022 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cell (iPSC) Global Market Report 2022, By Derived Cell Type, By Application, By End-User" report has been added to ResearchAndMarkets.com's offering.

The global induced pluripotent stem cell (iPSC) market is expected to grow from $ 2431.2 million in 2021 to $ 2640.80 million in 2022 at a compound annual growth rate (CAGR) of 8.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $ 3571.48 million in 2026 at a CAGR of 7.8%.

Increase in the prevalence of chronic disorders is one of the major factors that is driving the growth of Induced pluripotent stem cell market. Chronic disorders like heart disease, cancer, stroke, diabetes can be treated with Induced pluripotent stem cell.

Induced Pluripotent stem cells are taken from any tissues from a child or an adult and are genetically modified to behave like embryonic stem cells. According to the report published by Partnership to Fight Chronic Disorder (PFCD), it was found that out of 133 million Americans, 45% of the population had at least one chronic disorder. Moreover, it was estimated that 7 out of 10 deaths in the USA, which is approximately 1.7 million, are due to chronic disorders and these deaths can be controlled by induced pluripotent stem cell treatment. This rise in incidences of chronic diseases is driving the demand for induced pluripotent stem cell treatment.

The potential risk of tumour is one of the major restraints on the growth of Induced pluripotent stem cell market. As per a scientific research, it was found that there might be a chance of getting cancer from the treatment and people are unwilling to take treatment through Induced pluripotent stem cell therapy.

According to the report by American Association for cancer research, in most of the cases while doing the experiment it was found that the occurrence of the tumours was prevalent after a short period of time. This risk of developing a tumour due to Induced pluripotent stem cell therapy is limiting the number of patients opting for this treatment, thereby restraining the growth of the market.

ScopeMarkets Covered:1) By Derived Cell Type: Hepatocytes; Fibroblasts; Keratinocytes; Amniotic Cells; Others2) By Application: Academic Research; Drug Development And Discovery; Toxicity Screening; Regenerative Medicine3) By End-User: Hospitals; Research Laboratories

Key Topics Covered:

1. Executive Summary

2. Induced Pluripotent Stem Cell (iPSC) Market Characteristics

3. Induced Pluripotent Stem Cell (iPSC) Market Trends And Strategies

4. Impact Of COVID-19 On Induced Pluripotent Stem Cell (iPSC)

5. Induced Pluripotent Stem Cell (iPSC) Market Size And Growth

6. Induced Pluripotent Stem Cell (iPSC) Market Segmentation

7. Induced Pluripotent Stem Cell (iPSC) Market Regional And Country Analysis

8. Asia-Pacific Induced Pluripotent Stem Cell (iPSC) Market

9. China Induced Pluripotent Stem Cell (iPSC) Market

10. India Induced Pluripotent Stem Cell (iPSC) Market

11. Japan Induced Pluripotent Stem Cell (iPSC) Market

12. Australia Induced Pluripotent Stem Cell (iPSC) Market

13. Indonesia Induced Pluripotent Stem Cell (iPSC) Market

14. South Korea Induced Pluripotent Stem Cell (iPSC) Market

15. Western Europe Induced Pluripotent Stem Cell (iPSC) Market

16. UK Induced Pluripotent Stem Cell (iPSC) Market

17. Germany Induced Pluripotent Stem Cell (iPSC) Market

18. France Induced Pluripotent Stem Cell (iPSC) Market

19. Eastern Europe Induced Pluripotent Stem Cell (iPSC) Market

20. Russia Induced Pluripotent Stem Cell (iPSC) Market

21. North America Induced Pluripotent Stem Cell (iPSC) Market

22. USA Induced Pluripotent Stem Cell (iPSC) Market

23. South America Induced Pluripotent Stem Cell (iPSC) Market

24. Brazil Induced Pluripotent Stem Cell (iPSC) Market

25. Middle East Induced Pluripotent Stem Cell (iPSC) Market

26. Africa Induced Pluripotent Stem Cell (iPSC) Market

27. Induced Pluripotent Stem Cell (iPSC) Market Competitive Landscape And Company Profiles

28. Key Mergers And Acquisitions In The Induced Pluripotent Stem Cell (iPSC) Market

29. Induced Pluripotent Stem Cell (iPSC) Market Future Outlook and Potential Analysis

30. Appendix

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/mkszf2

Follow this link:
Induced Pluripotent Stem Cell (iPSC) Global Market to Reach $3.57 Billion by 2026 - Benzinga

Posted in Stem Cell Therapy | Comments Off on Induced Pluripotent Stem Cell (iPSC) Global Market to Reach $3.57 Billion by 2026 – Benzinga

Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies – PR…

Posted: August 5, 2022 at 2:51 am

Leveraging Poseida's novel approach to cell therapy and Roche's expertise in developing and commercializing therapies to transform cancer care, the collaboration is focused on advancing multiple existing and additional next generation allogeneic CAR-T programs directed to hematologic malignancies

Poseida will receive $110 million upfront, could receive up to $110 million in near-term milestones and other payments, and is eligible for future development and commercial milestones and tiered royalty payments

Poseida to host a brief conference call today at 8:30 a.m. ET

SAN DIEGO, Aug.3, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced it has entered into a broad strategic collaboration and license agreement with Roche, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. The global collaboration covers the research and development of multiple existing and novel "off-the-shelf" cell therapies against targets in multiple myeloma, B-cell lymphomas and other hematologic indications.

"We are excited to partner and collaborate with Roche, one of the world's largest biotechnology companies, which has a successful track record in the discovery, development and commercialization of innovative medicines," said Mark Gergen, Chief Executive Officer of Poseida. "Roche is an ideal strategic partner for Poseida with its industry-leading R&D capabilities in oncology, complementary technologies and expertise, and global regulatory and commercial capabilities. Working together, we look forward to advancing novel allogeneic cell therapies based upon Poseida's technologies for patients battling cancer."

Poseida Therapeutics announces strategic global collaboration with Roche focused on #allogeneic CAR-T cell therapies.

Under the agreement, Roche will receive from Poseida either exclusive rights or options to develop and commercialize a number of allogeneic CAR-T programs in Poseida's portfolio that are directed to hematologic malignancies, including P-BCMA-ALLO1, an allogeneic CAR-T for the treatment of multiple myeloma and for which a Phase 1 study is underway, and P-CD19CD20-ALLO1, an allogeneic dual CAR-T for the treatment of B-cell malignancies with an IND expected in 2023. Building on complementary expertise and capabilities, the parties will also collaborate in a research program to create and develop next-generation features and improvements for allogeneic CAR-T therapies, from which they would jointly develop additional allogeneic CAR-T product candidates directed to existing and new hematologic targets. For a subset of both the Poseida portfolio programs licensed or optioned to Roche and the parties' future collaboration programs, Poseida will conduct the Phase 1 studies and manufacture clinical materials before transitioning the programs to Roche for further development and commercialization. Roche will be solely responsible for the late-stage clinical development and global commercialization of all products that are subject to the collaboration.

"We are excited to partner with Poseida to further explore the potential of allogeneic cell therapies to transform cancer care by developing off-the-shelf products that can address high unmet medical needs for a broad patient population," said James Sabry, Global Head of Pharma Partnering at Roche. "Poseida's differentiated platform technologies complement our ongoing internal efforts and partnerships to discover and develop cell therapies as a next generation of medicines for patients."

Under the agreement, Poseida will receive $110 million upfront and could receive up to $110 million in near-term milestonesand other payments in the next several years. In addition, Poseida is eligible to receive research, development, launch, and net sales milestones and other payments potentially up to $6 billion in aggregate value, as well as tiered net sales royalties into the low double digits, across multiple programs.

"We are thrilled that Roche has embraced the opportunity to partner with us and use Poseida's unique allogeneic approach to develop CAR-T product candidates," said Devon J. Shedlock, Ph.D., Chief Scientific Officer, Cell Therapy at Poseida. "Using our proprietary technologies and manufacturing process including our booster molecule, we have the potential to develop and manufacture a product with high levels of stem cell memory T cells, which are correlated with potent antitumor efficacy in the clinic, at a scale that can potentially reach more patients and enable broad commercial use."

The effectiveness of the agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act).

Poseida Therapeutics Conference Call and Webcast InformationWednesday, August 3, 2022 at 8:30 a.m. ET

Poseida's management team will host a conference call and webcast today at 8:30 a.m. ET to discuss the collaboration and Poseida's novel approach to allogeneic cell therapy. The dial-in numbers for domestic and international callers are 800-267-6316 and 203-518-9814, respectively. The conference ID number for the call is PSTX0803.

Participants may access the live webcast on the Investors & Media Section of the Poseida website, http://www.poseida.com. An archived replay of the webcast will be available for approximately 30 days following the event.

About Poseida Therapeutics, Inc.

Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-specific Gene Editing System and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics. To learn more, visit http://www.poseida.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the upfront payment and other potential fees, milestone and royalty payments and development activities under the collaboration agreement, the potential benefits of Poseida's technology platforms and product candidates, the clearance of the collaboration agreement under the HSR Act, Poseida's plans and strategy with respect to developing its technologies and product candidates, and anticipated timelines and milestones with respect to Poseida's development programs and manufacturing activities. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Poseida's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the fact that the collaboration agreement may not become effective based on HSR Act clearance, or the effectiveness may be substantially delayed, or may be terminated early, the fact that the Company will have limited control over the efforts and resources that Roche devotes to advancing development programs under the collaboration agreement and Poseida may not receive the potential fees and payments under the collaboration agreement or fully realize the benefits of the collaboration, risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry, the fact that future preclinical and clinical results could be inconsistent with results observed to date, and the other risks described in Poseida's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Poseida undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

SOURCE Poseida Therapeutics, Inc.

See more here:
Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies - PR...

Posted in Stem Cell Therapy | Comments Off on Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies – PR…

World to Witness Surging Use of Neurostimulation & Neuromodulation Devices for Nerve Repair and Regeneration, Predicts Fact.MR – GlobeNewswire

Posted: August 5, 2022 at 2:51 am

United States, Rockville MD, Aug. 04, 2022 (GLOBE NEWSWIRE) -- As per an in-depth industry analysis by Fact.MR, a market research and competitive intelligence provider, global demand for nerve repair and regeneration devices is expected to reach a valuation of US$ 12 billion by 2026, rising at a high CAGR of 11% over the forecast period (2022-2026).

The ageing population, which is more prone to neurological illnesses, and the rise in nerve injuries, are factors fueling market growth. Hospitals, ambulatory surgery centers, and other healthcare institutions across the world are providing innovative solutions for the fast diagnosis and treatment of neurological disorders. Through nerve repair and regeneration, damaged neural tissue, cells, and cellular byproducts can be replaced.

For Critical Insights on Nerve Repair and Regeneration Market, Request a Sample Reporthttps://www.factmr.com/connectus/sample?flag=S&rep_id=7585

Several technological advancements in stem cell therapy and the introduction of novel neuromodulation devices are driving market growth. Many additional reasons, such as increased consumer healthcare spending and major advancements in medical infrastructure, particularly in developing nations, are likely to boost market expansion. Clinical trials are also being carried out by organizations with support from the public and commercial sectors to provide a safe and effective remedy for a variety of neurological diseases.

What Could Start-ups Do to Boost Their Business Potential?

Emerging Market Participants Concentrating on Introduction of New Products to Improve Health after Nerve Injury

New companies are concentrating on the development and commercialization of implantable solutions to enhance the effectiveness of peripheral nerve restoration surgeries.

New market entrants are engaged in introducing nerve regeneration supplements and nerve repair medicines to speed up healing and improve health after nerve injury.

To learn more about Nerve Repair and Regeneration Market, you can get in touch with our Analyst at https://www.factmr.com/connectus/sample?flag=AE&rep_id=7585

Key Segments Covered in the Nerve Repair and Regeneration Industry Survey

Competitive Landscape

Key companies are investing in R&D operations to create innovative devices and ways to give patients up-to-date, accurate treatment. In the market for nerve repair and regeneration, these strategies are supporting manufacturers in securing a dominant position and extending their global reach. Development of the market for nerve repair and regeneration also highly depends on strategic alliances.

For instance,

Get Customization on Nerve Repair and Regeneration Market Report for Specific Research Solutionshttps://www.factmr.com/connectus/sample?flag=RC&rep_id=7585

Key players in the Nerve Repair and Regeneration Market

Key Takeaways from Nerve Repair and Regeneration Market Study

About the Healthcare Division at Fact.MR

Our healthcare consulting team guides organizations at each step of their business strategy by helping you understand how the latest influencers account for operational and strategic transformation in the healthcare sector. Our expertise in recognizing the challenges and trends impacting the global healthcare industry provides indispensable insights and support - encasing a strategic perspective that helps you identify critical issues and devise appropriate solutions.

Explore Fact.MR's Coverage on the Healthcare Domain-

Dental Radiology Equipment Market- According to Fact.MR, the global dental radiology equipment market was valued at around US$ 7 Bn in 2020, and is projected to expand 1.4X to top US$ 10 Bn by 2031.

Personal Dental Water Flosser Market- According to Fact.MRs personal dental water flosser industry research, the global market was valued at US$ 196 Mn in 2020, and is projected to top US$ 292 Mn by 2031, expanding at a CAGR of 6% across the 2021-2031 forecast period.

Dental Diagnostic Imaging Equipment Market- Fact.MRs dental diagnostic imaging equipment industry research reveals that the global market was valued at US$ 2 Bn in 2020, and is projected to top US$ 3 Bn by 2031, expanding at a CAGR of 6%. Demand for X-ray systems is projected to increase at a CAGR of 5% through 2031, with that for dental cone beam computed tomography surging at 7%.

Dental Membrane and Bone Graft Substitutes Market- According to Fact.MR, the global dental membrane and bone graft substitutes market was valued at around US$ 500 Mn in 2020, and is projected to expand 1.8X to top US$ 900 Mn by 2031.

Interdental Cleaning Products Market- Fact.MRs interdental cleaning products industry analysis shows that the global market was valued at US$ 3 Bn in 2020, and is projected to top US$ 4 Bn by 2031, expanding at a CAGR of 3%. Demand for interdental brushes is projected to expand at a CAGR of 5%, reaching a valuation of around US$ 1 Bn by 2031, with that for toothpicks is increasing at 4%.

Europe Diet Pills Market- Newly released data in Fact.MRs market analysis shows that demand for diet pills in Europe is expected to increase at a CAGR of 2.6% through 2031, with the market being valued at US$ 669 Mn currently.

Medical Radiation Detection, Monitoring and Safety Market- According to Fact.MR, the global medical radiation detection, monitoring and safety market was valued at around US$ 880 Mn in 2020, and is projected to expand 1.7X to top US$ 1.5 Bn by 2031.

Americas Hematology Diagnostics Market- As per industry analysis of the Americas hematology diagnostics market, revenue totaled US$ 264 Mn in 2020, according to Fact MR. The market is expected to progress at a CAGR of 5% through 2031.

Wireless Portable Medical Devices Market- Fact.MRs wireless portable medical devices industry analysis reveals that the global market was valued at US$ 15 Bn in 2020, and is projected to top US$ 33 Bn by 2031, expanding at a CAGR of 11%. Demand for monitoring devices is projected to expand at a CAGR of 11% reaching a valuation of around US$ 16 Bn, with that for medical therapeutic devices also surging at 11%.

Americas Hospital Acquired Infection Testing Market- Fact.MR's Americas hospital acquired infection testing industry analysis predicts the market to attain a valuation of US$ 2.7 Bn by the end of the decade, which is more than 4X more than its worth at present.

About Us:Market research and consulting agency with a difference! Thats why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and well be an able research partner.

Contact:Mahendra SinghUS Sales Office:11140 Rockville PikeSuite 400Rockville, MD 20852Email: sales@factmr.com Tel: +1 (628) 251-1583Follow Us: LinkedIn | Twitter

Read more from the original source:
World to Witness Surging Use of Neurostimulation & Neuromodulation Devices for Nerve Repair and Regeneration, Predicts Fact.MR - GlobeNewswire

Posted in Stem Cell Therapy | Comments Off on World to Witness Surging Use of Neurostimulation & Neuromodulation Devices for Nerve Repair and Regeneration, Predicts Fact.MR – GlobeNewswire

The Role of Cell Banking Outsourcing Market Industry Growth, Competitors Analysis, New Technology, Trends and Forecast 2020 2030 – Digital Journal

Posted: August 5, 2022 at 2:51 am

Global Cell Banking Outsourcing Market: Overview

The global cell banking outsourcing market is likely to be driven by the rising demand for biopharmaceutical production targeting novel active sites, stem cell therapy, and gene therapy. A cell bank is a facility storing cells extracted from various organ tissue and body fluids so as to cater to the needs of the future. The cell banks make storage of cells with an elaborate characterization of the entire cell line as it reduces the possibilities of cross contamination. These benefits are estimated to fuel expansion of the global cell banking outsourcing market over the timeframe of assessment, from 2020 to 2030.

Cell banking outsourcing industries engage testing, characterization, storage, and collection of tissues, cell lines, and the cells. These activities are done to assist in the production of biopharmaceuticals and in the research and development activities so as to ensure minimum adverse effects and high effectiveness. The procedure of the cell storage involves first proliferation of cells, which then multiplies in a huge number of identical cells and is then put inside cryovials safety for use in future. Cells are primarily utilized in the production of regenerative medicine. A surge in the number of cell banks together with the high demand for stem cell therapies is likely to work in favor of the global cell banking outsourcing market over the tenure of analysis, from 2020 to2030.

The global cell banking outsourcing market has been segmented on the basis of four important parameters, which are bank type, phase, cell type, and region.

Request Brochure of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=79685

Global Cell Banking Outsourcing Market: Notable Developments

The global cell banking outsourcing market is considered a fairly competitive market and is marked with the presence of many leading market players. The companies in this market are forging mergers, partnerships, and collaborations so as to gain larger revenue and market share. The following development is expected to play an important role in the market:

In June 2017, Swedish pharmaceutical company, Alligator BioscienceAB, entered into partnership with a leading French biopharma company, Sartorius Stedim BiotechS.A. In this partnership, Alligator Bioscienceis the cell line development partner in the development of immuno-oncology antibody drug candidate.

Request For Custom Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=79685

Some of the prominent organizations in the global cell banking outsourcing market comprise the below-mentioned:

Global Cell Banking Outsourcing Market: Key Trends

The global cell banking outsourcing market is characterized by the presence of the following restraints, drivers, and opportunities.

High Demand for Stem Cell Therapies to Trigger Growth of the Market

The rising number of stem cell therapies across the globe primarily influences the global cell banking outsourcing market. According to a survey conducted by World Network for Blood and Marrow Transplantation (WBMN), nearly 1 million hematopoietic stem cell transplantation processes were conducted in between 2006 to 2014. These figure comprised removal of stem cells procedures from peripheral blood or bone marrow, proliferating, and then finally storing them cell banks for future use by patients. Stem cell therapies are able to multiple disease, such as amyotrophic lateral sclerosis, type 1 diabetes, cancer, Alzheimers disease, Parkinsons disease, and so on. Ability to cure such a wide variety of diseases is expected to propel growth of the global cell banking outsourcing market in the years to come.

Make an Enquiry before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=79685

Global Cell Banking Outsourcing Market: Geographical Analysis

North America is expected to dominate the global cell banking outsourcing market throughout the timeframe of analysis, from 2020 to 2030. Such high growth of the North America market is ascribed to the increased production of antibiotics, therapeutics protein, and vaccines. In addition, presence of several biopharmaceutical companies in the region is anticipated to foster growth of the cell banking outsourcing market in North America in the near future.

More Related Reports by Transparency Market Research

Medical Protective Equipment Market: https://www.transparencymarketresearch.com/medical-protective-equipment-market.html

BiPAP Machines Market: https://www.transparencymarketresearch.com/bipap-machines-market.html

Telemedicine Technologies and Services Market: https://www.transparencymarketresearch.com/telemedicine-technologies-market.html

Genomic and Proteomic Tools Market: https://www.transparencymarketresearch.com/genomic-and-proteomic-tools-market.html

Drug Delivery Technology Market: https://www.transparencymarketresearch.com/drug-delivery-technology-market.html

3D Printed Medical Implants Market: https://www.transparencymarketresearch.com/3d-printed-medical-implants-market.html

Depth of Anesthesia Monitoring Devices Market: https://www.transparencymarketresearch.com/depth-of-anesthesia-monitoring-devices-market.html

Healthcare Contract Research Outsourcing Market: https://www.transparencymarketresearch.com/hcro-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services The firm scrutinizes factors shaping the dynamics of demand in various markets.The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website:https://www.transparencymarketresearch.comBlog:https://tmrblog.comEmail:%5Bemailprotected%5D

Continued here:
The Role of Cell Banking Outsourcing Market Industry Growth, Competitors Analysis, New Technology, Trends and Forecast 2020 2030 - Digital Journal

Posted in Stem Cell Therapy | Comments Off on The Role of Cell Banking Outsourcing Market Industry Growth, Competitors Analysis, New Technology, Trends and Forecast 2020 2030 – Digital Journal

Dr. Owhofasa Agbedia Honored With The 2022 ASH-CIBMTR-ASTCT Career Development Award – Business Wire

Posted: August 5, 2022 at 2:51 am

MINNEAPOLIS--(BUSINESS WIRE)--The Center for International Blood and Marrow Transplantation (CIBMTR), is delighted to announce that Owhofasa Agbedia, MD, MPH, has been selected to receive the ASH-CIBMTR-ASTCT Career Development Award. The award includes a stipend of $100,000 to conduct clinical or laboratory-based hematology research projects and to be mentored in person by faculty at the CIBMTRs two parent institutions.

The CIBMTR is a research collaboration between the National Marrow Donor Program (NMDP)/Be The Match and the Medical College of Wisconsin (MCW). The award is part of a program to increase racial and ethnic diversity in the next generation of medical professionals.

NMDP/Be The Match is proud to provide Dr. Agbedia mentorship and support research with ASH and the CIBMTR that will positively impact patients and expand representation in our field, said Stephen Spellman, Vice President, Research, NMDP/Be The Match. We believe that diversity, equity, and inclusion in our field are essential to innovation and eliminating health care disparities.

Dr. Agbedia is a fellow, Hematology/Oncology at UT MD Anderson Cancer Center and a graduate student at MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences. Dr. Agbedia is interested in investigating an innovative cellular therapeutic option for treating CD94-expressing NK/T-cell lymphoproliferative disorders.

Along with our partner organizations, the CIBMTR is committed to supporting the career development of our next generation, particularly those with diverse backgrounds. In so doing, we ensure the future success of our field by fostering the minds and hearts of those who will discover novel approaches to improve patient outcomes, said CIBMTR Chief Scientific Director Jeffery Auletta, MD.

The award enrolls Dr. Agbedia in the American Society for Transplant and Cellular Therapy (ASTCT) Leadership and the ASTCT Clinical Research Training courses and includes membership on the ASTCT Committee on Diversity and Inclusion. Dr. Agbedia receives registration for the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. Additionally, Dr. Agbedia will be invited to present research findings during the Promoting Minorities in Hematology event at the ASH Annual Meeting and Exposition.

The CIBMTR/American Society of Hematology, (ASH)/American Society of Transplantation and Cellular Therapy (ASTCT) award is part of the ASH Minority Hematology Fellow Award (MHFA) program, which supports early-career researchers from racial and ethnic groups that were historically underrepresented in medicine. This award is exclusively for fellows pursuing careers in hematopoietic stem cell transplantation and cellular therapy. It is one of six programs under ASHs Minority Recruitment Initiative, a series of programs committed to increasing racial and ethnic diversity in physicians training in hematology-related fields and in hematologists with academic and research appointments.

Background:

The National Marrow Donor Program (NMDP)/Be The Match is the leading global partner working to save lives through cellular therapy. With more than 35 years of experience managing the most diverse registry of potential unrelated blood stem cell donors and cord blood units worldwide, NMDP/Be The Match is a proven partner in providing cures to patients with life-threatening blood and marrow cancers and diseases. Its global network connects centers and patients to their best cell therapy option. It is a tireless advocate for the cell therapy community, working with hematologists/oncologists to remove barriers to consultation and treatment and supporting patients through no-cost programs to eliminate non-medical obstacles to cell therapy. NMDP/Be The Match is a global leader in research through the CIBMTR, investing in and managing research studies that improve patient outcomes and advance the future of care.

The CIBMTR (Center for International Blood and Marrow Transplant Research) is a research collaboration between the National Marrow Donor Program (NMDP)/Be The Match and the Medical College of Wisconsin (MCW). The CIBMTR collaborates with the global scientific community to advance hematopoietic cell transplantation (HCT) and cellular therapy worldwide to increase survival and enrich the quality of life for patients. The CIBMTR facilitates critical observational and interventional research through scientific and statistical expertise, a large network of transplant centers, and a unique and extensive clinical outcomes database. For more information on the CIBMTR, please visit http://www.cibmtr.org or follow the CIBMTR on Facebook, LinkedIn, or Twitter at @CIBMTR.

The American Society of Hematology (ASH) (www.hematology.org) is the worlds largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 60 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. ASH publishes Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, and Blood Advances (www.bloodadvances.org), an online, peer-reviewed open-access journal.

The American Society for Transplantation and Cellular Therapy (ASTCT), with headquarters in Chicago, is a professional society over 3,000 00 healthcare professionals and scientists from more than 45 countries who are dedicated to improving the application and success of blood and marrow transplantation and related cellular therapies. ASTCT strives to be the leading organization promoting research, education and clinical practice to deliver the best, comprehensive patient care.

Excerpt from:
Dr. Owhofasa Agbedia Honored With The 2022 ASH-CIBMTR-ASTCT Career Development Award - Business Wire

Posted in Stem Cell Therapy | Comments Off on Dr. Owhofasa Agbedia Honored With The 2022 ASH-CIBMTR-ASTCT Career Development Award – Business Wire

Page 292«..1020..291292293294..300310..»